Asymmetric dimethylarginine (ADMA): An endogenous inhibitor of NO synthase - Also a risk marker for preeclampsia?;Asymmetrisches dimethylarginin (ADMA): Ein endogener hemmstoff der NO-synthase - Und auch ein risikomarker der präeklampsie?

Geburtshilfe und Frauenheilkunde

Volumn 67, Issue 6, 2007, Pages 611-619

  Maas, R ^a   Baschat, A ^a   Hecher, K ^a   Böger, Rainer H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cardiovascular disease; Endothelium; L arginine; Pregnancy; Risk marker

Indexed keywords

ARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR;

BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HYPERTENSION; MATERNAL MORBIDITY; NEWBORN MORBIDITY; PREECLAMPSIA; PREGNANCY; REVIEW;

EID: 34547095775     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-965092     Document Type: Review

References (82)

1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365: 785-799
2. MacKay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from pre-eclampsia and eclampsia. Obstet Gynecol 2001; 97: 533-538
3. Welsch H, Krone HA. Mütterliche Mortalität bei HELLP-Syndrom in Bayern 1983-1992. Zentralbl Gynäkol 1994; 116: 202-206
4. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001; 357: 53-56
5. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005; 308: 1592-1594
6. Sibai BM, Ewell M, Levine RJ, Klebanoff MA, Esterlitz J, Catalano PM, Goldenberg RL, Joffe G. Risk factors associated with preeclampsia in healthy nulliparous women. Am J Obstet Gynecol 1997; 177: 1003-1010
7. Tsukimori K, Ishida K Maeda H, Koyanagi T, Nakano H. The placenta as a possible source of the factor causing endothelial cell injury in preeclampsia. Hypertens Pregn 1994; 13: 358
8. Cross JC. Trophoblast function in normal and preeclamptic pregnancy. Fetal Matern Med Rev 1996; 8: 57-66
9. Endresen MJ, Tosti E, Heimli H, Lorentzen B, Henriksen T. Effects of free fatty acids found increased in women who develop preeclampsia on the ability of endothelial cells to produce prostacyclin, cGMP and inhibit platelet aggregation. Scand J Clin Lab Invest 1994; 54: 549-557
10. Sattar N, Gaw A, Packard CJ, Greer IA. Potential pathogenetic roles of aberrant lipoprotein and fatty acid metabolism in preeclampsia. Br J Obstet Gynaecol 1996; 103: 614-620
11. Redman CWG. Immunology of preeclampsia. Semin Perinatol 1991; 15: 257-262
12. Stark JM. Preeclampsia and cytokine-induced oxidative stress. Br J Obstet Gynaecol 1993; 100: 105-109
13. Meekins JW, McLaughlin PJ, West DC, MacFadyen IR, Johnson PM. Endothelial cell activation by tumor necrosis factor-alpha (TNF-alpha) and the development of preeclampsia. Clin Exp Immunol 1994; 98: 110-114
14. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol1989; 161: 1200
15. Seligman SP, Buyon JP, Clancy RM, Young BK, Abramson SB. The role of nitric oxide in the pathogenesis of preeclampsia. Am J Obstet Gynecol 1994; 171: 944-948
16. Lopez-Jaramillo P, Narvaez M, Calle A, Rivera J, Jacome P, Ruano C, Nava E. Cyclic guanosine 3′, 5′ monophosphate concentrations in pre-eclampsia: Effects of hydralazine. Br J Obst Gynecol 1996; 103: 33-38
17. Williams DJ, Vallance PJT, Neild H, Spencer JAD, Imms FJ. Nitric oxide-mediated vasodilation in human pregnancy. Am J Physiol 1997; 272: H748-H752
18. Lopez-Jaramillo P. Calcium, nitric oxide, and preeclampsia. Semin Perinatol 2000; 24: 33-36
19. Beinder E, Frobenius W. Die Präeklampsie: Eine Endothelerkrankung? Dt Ärztebl 2000; 97: A2703-2706
20. Baylis C, Beinder E, Sütö T, August P. Recent insights into the roles of nitric oxide and renin-angiotensin in the pathophysiology of preeclamptic pregnancy. Semin Nephrol 1998; 18: 208-230
21. Sladek SM, Magness RR, Conrad KP. Nitric oxide and pregnancy. Am J Physiol 1997; 272: R441-R463
22. Buhimschi IA, Saade GR, Chwalisz K, Garfield RE. The nitric oxide pathway in pre-eclampsia: pathophysiological implications. Hum Reprod Update 1998; 4: 25-42
23. Kobayashi T, Tokunaga N, Isoda H, Kanayama N, Terao T. Vasospasms are characteristic in cases with eclampsia/preeclampsia and HELLP syndrome: proposal of an angiospastic syndrome of pregnancy. Semin Thromb Hemost 2001; 27: 131-135
24. Lowe DT. Nitric oxide dysfunction in the pathophysiology of preeclampsia. Nitric Oxide 2000; 4: 441-458
25. Khan F, Belch JJ, MacLeod M, Mires G. Changes in endothelial function precede the clinical disease in women in whom preeclampsia develops. Hypertension 2005; 46: 1123-1128
26. Myers J, Mires G, Macleod M, Baker P. In preeclampsia, the circulating factors capable of altering in vitro endothelial function precede clinical disease. Hypertens 2005; 45: 258-263
27. Förstermann U, Closs EI, Pollock JS et al. Nitric oxide synthase isoenzymes. Characterization, purification, molecular cloning, and functions. Hypertension 1994; 23: 1121-1131
28. Furchgott RF. The role of endothelium in the responses of vascular smooth muscle to drugs. Annu Rev Pharmacol Toxicol 1984; 24: 175-197
29. Böger RH, Bode-Böger SM, Frölich JC. The L-arginine-nitric oxide pathway: Role in atherosclerosis and therapeutic implications. Atherosclerosis 1996; 127: 1-11
30. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet 1992; 339: 572-575
31. Böger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, Tsikas D, Bode-Böger SM. LDL cholesterol upregulates synthesis of asymmetric dimethylarginine (ADMA) in human endothelial cells. Involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000; 87: 99-105
32. Tsikas D, Sandmann J, Böger RH, Gutzki FM, Mayer B, Frölich JC. Assessment of nitric oxide synthase activity by gas chromatography-mass spectrometry. J Chromatogr B 2000; 742: 143-153
33. Böger RH, Bode-Böger SM, Thiele W, Junker W, Alexander K, Frölich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95: 2068-2074
34. Valkonen VP, Päivä H, Salonen JT, Lakka TA, Lehtimäki T, Laakso J, Laaksonen R. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358: 2127-2128
35. Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Jachmann N, Post F, Peetz D, Bickel C, Cambien F, Tiret L, Münzel T. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005; 97: e53-59
36. Calver A, Collier J, Leone A, Moncada S, Vallance P. Effect of local intra-arterial asymmetric dimethylarginine (ADMA) on the forearm arteriolar bed of healthy volunteers. J Hum Hypertens 1993; 7: 193-194
37. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC, Hoeper MM, Haller H, Fliser D. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004; 109: 172-177
38. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolised by dimethylarginine dimethylaminohydolase. Arterioscler Thromb Vasc Biol 2003; 23: 1455-1459
39. Böger RH, Bode-Böger SM, Szuba A, Tangphao O, Tsao PS, Chan JR, Blaschke TF, Cooke JP. Asymmetric dimethylarginine: a novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation 1998; 98: 1842-1847
40. Lundman P, Eriksson MJ, Stühlinger M, Cooke JP, Hamsten A, Tornvall P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001; 38: 111-116
41. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Böger RH, Bode-Böger SM, Kruszelnicka-Kwiatkowska O, Kokot F, Dubiel J, Frölich JC. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652-658
42. Gorenflo M, Zheng C, Werle E, Fiehn W, Ulmer HE. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol 2001; 37: 489-492
43. Kielstein JT, Böger RH, Bode-Böger SM, Schäffer J, Barbey M, Koch KM, Frölich JC. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999; 10: 594-600
44. Usui M, Matsuoka H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure. Life Sci 1998; 62: 2425-2430
45. Abbasi F, Asagami T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, Stuehlinger M, Tsao PS. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88: 1201-1203
46. Yoo JH, Lee SC. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis 2001; 158: 425-430
47. Tsikas D, Rode I, Becker T, Nashan B, Klempnauer J, Frölich JC. Elevated plasma and urine levels of ADMA and 15(S)-8-iso-PGF2alpha in end-stage liver disease. Hepatology 2003; 38: 1063-1064
48. Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet 1993; 341: 1447-1451
49. Hayman R, Warren A, Johnson I, Baker P. The preliminary characterization of a vasoactive circulating factor(s) in preeclampsia. Am J Obstet Gynecol 2001; 184: 1196-1203
50. Fickling SA, Williams D, Vallance P, Nussey SS, Whitley GSJ. Plasma concentrations of endogenous inhibitor of nitric oxide synthesis in normal pregnancy and pre-eclampsia. Lancet 1993; 342: 242-243
51. Holden DP, Fickling SA, Whitley GSJ, Nussey SS. Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. Am J Obstet Gynecol 1998; 178: 551-556
52. Pettersson A, Hedner T, Milsom I. Increased circulating concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Acta Obstet Gynecol Scand 1998; 77: 808-813
53. Ellis J, Wennerholm UB, Bengtsson A, Lilja H, Pettersson A, Sultan B, Wennergren M, Hagberg H. Levels of dimethylarginines and cytokines in mild and severe preeclampsia. Acta Obstet Gynecol Scand 2001; 80: 602-608
54. Savvidou MD, Hingorani AD, Tsikas D, Frölich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 2003; 361: 1511-1517
55. Maas R, Serrano N, Schwedhelm E, Diaz LA, Casas JP, Böger RH, Lopez-Jaramillo P. Plasma concentration of asymmetrical dimethylarginine (ADMA) in women with pre-eclampsia from a high-risk population. J Am Med Assoc 2004; 291: 823-824
56. Lopez-Jaramillo P, Casas JP, Serrano N. Preeclampsia: from epidemiological observations to molecular mechanisms. Braz J Med Biol Res 2001; 34: 1227-1235
57. Mittermayer F, Mayer BX, Meyer A, Winzer C, Pacini G, Wagner OF, Wolzt M, Kautzky-Willer A. Circulating concentrations of asymmetrical dimethyl-L-arginine are increased in women with previous gestational diabetes. Diabet 2002; 45: 1372-1378
58. Stühlinger M, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. J Am Med Assoc 2002; 287: 1420-1426
59. Momohara Y, Sakamoto S, Obayashi S, Aso T, Goto M, Azuma H. Roles of endogenous nitric oxide synthase inhibitors and endothelin-1 for regulating myometrial contractions during gestation in the rat. Mol Hum Reprod 2004; 10: 505-512
60. Noris M, Todeschimi M, Cassis P, Pasta F, Cappellini A, Bonazzola S, Macconi D, Maucci R, Porrati F, Benigni A, Picciolo C, Remuzzi G. L-arginine depletion in preeclampsia orients nitric oxide synthase toward oxidant species. Hypertension 2004; 43: 614-622
61. Loyaga-Rendon RY, Sakamoto S, Beppu M, Aso T, Ishizaka M, Takahashi R, Azuma T. Accumulated endogenous nitric oxide synthase inhibitors, enhanced arginase activity, attenuated dimethylarginine dimethylaminohydrolase activity and intimal hyperplasia in premenopausal human uterine arteries. Atherosclerosis 2005; 178: 231-239
62. MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, Hodson H, Whitley GS, Vallance P. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119: 1533-1540
63. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, Vallance P. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 1999; 343: 209-214
64. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction. Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99: 3092-3095
65. Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway. Role of asymmetric dimethylarginine. Circulation 2001; 104: 2569-2575
66. Schwedhelm E. Quantification of ADMA: analytical approaches. Vasc Med 2005; 10: S89-S95
67. Schwedhelm E, Tan-Andresen J, Maas R, Riederer U, Schulze F, Böger RH. Liquid chromatography-tandem mass spectrometry method for the analysis of asymmetric dimethylarginine in human plasma. Clin Chem 2005; 51: 1268-1271
68. Schwedhelm E, Maas R, Tan-Andresen J, Schulze F, Riederer U, Böger RH. High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J Chromatogr B 2007; in press
69. Schulze F, Wesemann R, Schwedhelm E, Sydow K, Albsmeier J, Cooke JP, Böger RH. Determination of ADMA using a novel ELISA assay. Clin Chem Lab Med 2004; 42: 1377-1383
70. Schulze F, Maas R, Freese R, Schwedhelm E, Silberhorn E, Böger RH. Determination of a reference value for N,N-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest 2005; 35: 622-626
71. Slaghekke F, Dekker G, Jeffries B. Endogenous inhibitors of nitric oxide and preeclampsia: A review. J Mat Neonat Med 2006; 19: 447-452
72. Böger RH, Bode-Böger SM, Thiele W, Creutzig A, Alexander K, Frölich JC. Restoring vascular NO formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol 1998; 32: 1336-1344
73. Rector TS, Bank AJ, Mullen KA, Tschumperlin LK, Sih R, Pillai K, Kubo SH. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation 1996; 93: 2135-2141
74. Ceremuzynksi L, Chamiec T, Herbacynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol 1997; 80: 331-333
75. Böger RH, Bode-Böger SM. The clinical pharmacology of L-arginine. Annu Rev Pharmacol 2001; 41: 79-99
76. Facchinetti F, Longo M, Piccinini F, Neri I, Volpe A. L-arginine infusion reduces blood pressure in preeclamptic women through nitric oxide release. J Soc Gynecol Invest 1999; 6: 202-207
77. Staff AC, Berge L, Haugen G, Lorentzen B, Mikkelsen B, Henricksen T. Dietary supplementation with L-arginine or placebo in women with preeclampsia. Acta Obstet Gynecol Scand 2004; 83: 103-107
78. Germain AM, Valdés G, Romanik MC, Reyes MS. Evidence supporting a beneficial role for long-term L-arginine supplementation in high-risk pregnancies [Letter]. Hypertension 2004; 44: e1
79. Alexander BT, Llinas MT, Kruckeberg WC, Granger JP. L-arginine attenuates hypertension in pregnant rats with reduced uterine perfusion pressure. Hypertension 2004; 43: 832-836
80. Rytlewski K, Olszanecki R, Korbut R, Zdebski Z. Effects of prolonged oral supplementation with L-arginine on pressure and nitric oxide synthesis in preeclampsia. Eur J Clin Invest 2005; 35: 32-37
81. Rytlewski K, Olszanecki R, Lauterbach R, Grzyb A, Basta A. Effects of oral L-arginine on the foetal condition and neonatal outcome in preeclampsia: A preliminary report. Basic Clin Pharmacol Toxicol 2006; 99: 146-152
82. Neri I, Jasonni VM, Gori GF, Blasi I, Facchinetti F. Effect of L-arginine on blood pressure in pregnancy-induced hypertension: a randomized placebo-controlled trial. J Matern Fetal Neonatal Med 2006; 19: 277-281